Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 10/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10436830 | 0.88 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL297710 | 0.84 | HRH2 (0.43) | SMN1; SMN2ALDH1A1NPSR1KDM4E | |
| SCHEMBL20201503 | 0.82 | GNAI3 (0.52) | THRB | |
| SCHEMBL4363929 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2POLBNPSR1L3MBTL1KDM4E | |
| Sulfuric Acid SCHEMBL28081786 | 0.81 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL12992411 | 0.79 | PAOX (0.56) | SMN1; SMN2POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL10263618 | 0.79 | MEN1 (0.47) | POLBNPSR1L3MBTL1KDM4ETHRB | |
| SCHEMBL4508388 | 0.78 | HRH2 (0.42) | ALDH1A1KDM4E | |
| SCHEMBL10554722 | 0.78 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL972563 | 0.78 | KDM4E (0.46) | SMN1; SMN2ALDH1A1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1337513-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002036570-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | SMN1; SMN2 1997/4885ALDH1A1 3317/4885POLB 1028/4885 |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | NQO2, TPD52L2, MLX | SMN1; SMN2 3515/4885ALDH1A1 2334/4885POLB 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.